MITOTANE

Search structure
Trade Names:
Synonyms:
Status: Approved (1970)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: L01XX23
UNII: 78E4J5IB5J

Structure
InChI Key JWBOIMRXGHLCPP-UHFFFAOYSA-N
Smile Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1
InChI
InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H

Physicochemical Descriptors

Property Name Value
Molecular Formula C14H10Cl4
Molecular Weight 320.05
AlogP 5.93
Hydrogen Bond Acceptor 0.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 3.0
Polar Surface Area 0.0
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 18.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Cytochrome P450 11A1 inhibitor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- - - - 2.942
Enzyme Transferase
- 1300 - - -
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb
- - - - 4.66-8.35
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Adrenergic receptor
- 7347 - 2755 -
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Serotonin receptor
- 1402 - 3075 -
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Nucleotide-like receptor (family A GPCR) Adenosine receptor
- 7445 - 4208 -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC06 neurotransmitter transporter family
- 1001 - 1601 -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 107.64

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Adrenal Cortex Neoplasms 4 D000306 ClinicalTrials
Carcinoma 3 D002277 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 1 D064129 ClinicalTrials

Side Effects from Label

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
14.63
Nervous system disorders
12.81
Metabolism and nutrition disorders
9.61
Injury, poisoning and procedural complications
9.45
Psychiatric disorders
9.41
Gastrointestinal disorders
7.46
Investigations
6.8
Blood and lymphatic system disorders
4.43
Endocrine disorders
3.52
Vascular disorders
2.36
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.28
Reproductive system and breast disorders
2.24
Infections and infestations
2.2
Musculoskeletal and connective tissue disorders
2.03

Cross References

Resources Reference
CAS NUMBER 53-19-0
ChEBI 6954
ChEMBL CHEMBL1670
DrugBank DB00648
DrugCentral 1820
EPA CompTox DTXSID9020372
FDA SRS 78E4J5IB5J
Human Metabolome Database HMDB14786
Guide to Pharmacology 6957
PharmGKB PA164746157
PubChem 4211
SureChEMBL SCHEMBL4040
CONTENTS